Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

SONN

Sonnet BioTherapeutics Holdings Inc

Jun 25 • 04:00PM ET

0.9200

Dollar change +0.0040
Percentage change 0.44	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.28	Insider Own	9.14%	Shs Outstand	3.11M	Perf Week	-41.82%
Market Cap	2.86M	Forward P/E	-	EPS next Y	-2.52	Insider Trans	0.00%	Shs Float	2.83M	Perf Month	-38.67%
Income	-8.43M	PEG	-	EPS next Q	-0.77	Inst Own	2.04%	Short Float	12.17%	Perf Quarter	-55.84%
Sales	0.09M	P/S	31.79	EPS this Y	89.27%	Inst Trans	7.93%	Short Ratio	10.20	Perf Half Y	-50.54%
Book/sh	0.98	P/B	0.94	EPS next Y	-29.45%	ROA	-87.68%	Short Interest	0.34M	Perf Year	-94.19%
Cash/sh	1.22	P/C	0.75	EPS next 5Y	-	ROE	-200.09%	52W Range	0.90 - 16.50	Perf YTD	-47.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	74.20%	ROI	-267.96%	52W High	-94.42%	Beta	0.53
Dividend TTM	-	Quick Ratio	1.89	Sales past 5Y	-37.47%	Gross Margin	14.90%	52W Low	2.46%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	1.89	EPS Y/Y TTM	94.80%	Oper. Margin	-13472.18%	RSI (14)	24.56	Volatility	12.34% 8.71%
Employees	12	Debt/Eq	0.06	Sales Y/Y TTM	-53.29%	Profit Margin	-9087.11%	Recom	1.00	Target Price	11.50
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	101.05%	Payout	-	Rel Volume	2.81	Prev Close	0.92
Sales Surprise	-100.00%	EPS Surprise	110.00%	Sales Q/Q	-100.00%	Earnings	May 14 AMC	Avg Volume	33.76K	Price	0.92
SMA20	-41.27%	SMA50	-45.75%	SMA200	-50.23%	Trades		Volume	94,799	Change	0.44%

Jun-20-24 08:30AM	Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds (GlobeNewswire) -32.03%
Jun-13-24 08:00AM	Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain (GlobeNewswire)
May-28-24 08:00AM	Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting (GlobeNewswire)
May-22-24 07:00AM	Sonnet BioTherapeutics Announces Review of Strategic Alternatives (ACCESSWIRE) +5.45%
May-20-24 09:15AM	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target (ACCESSWIRE) -5.43%
09:53AM	Loading…
May-15-24 09:53AM	SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024 (InvestorPlace)
May-14-24 04:15PM	Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update (ACCESSWIRE)
May-06-24 07:00AM	Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference (ACCESSWIRE)
May-03-24 09:00AM	Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference (Newsfile)
Mar-19-24 07:30AM	Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting (ACCESSWIRE)
Mar-11-24 07:30AM	Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective (ACCESSWIRE) +11.89%
Feb-29-24 04:05PM	Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers (ACCESSWIRE) +10.67% -8.12%
Feb-14-24 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update (ACCESSWIRE)
Dec-21-23 08:00AM	Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy (ACCESSWIRE) +19.25%
Dec-14-23 04:15PM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update (ACCESSWIRE) -9.62%
07:30AM	Loading…
Oct-31-23 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview (ACCESSWIRE)
Oct-25-23 07:30AM	Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering (ACCESSWIRE) -28.73%
Oct-17-23 08:00AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (ACCESSWIRE)
Sep-20-23 07:30AM	Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology (ACCESSWIRE) -6.70%
Sep-19-23 08:30AM	Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance (ACCESSWIRE)
Aug-31-23 10:55AM	Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split (ACCESSWIRE) -28.34%
Aug-16-23 07:30AM	Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US (ACCESSWIRE) +16.17%
Aug-14-23 08:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update (ACCESSWIRE)
Jul-31-23 09:00AM	Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference (ACCESSWIRE)
Jun-28-23 08:00AM	Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -21.47%
Jun-23-23 08:00AM	Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
Jun-20-23 08:00AM	Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab (ACCESSWIRE) -19.24%
May-10-23 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update (ACCESSWIRE)
Apr-18-23 04:01PM	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting (ACCESSWIRE) -7.85% -8.88%
Apr-17-23 08:00AM	Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting (ACCESSWIRE)
04:31PM	Loading…
Mar-14-23 04:31PM	Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting (ACCESSWIRE) -7.64%
Feb-13-23 08:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update (ACCESSWIRE)
Feb-08-23 08:00AM	Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering (ACCESSWIRE) -9.24%
Feb-01-23 08:00AM	Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates (ACCESSWIRE) -6.09%
Jan-19-23 08:00AM	Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010 (ACCESSWIRE)
Jan-09-23 08:00AM	Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer (ACCESSWIRE)
Dec-15-22 04:05PM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update (ACCESSWIRE)
Nov-02-22 08:00AM	Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010 (ACCESSWIRE) -27.56%
Nov-01-22 04:05PM	Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Companys Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022 (ACCESSWIRE) +46.63%
Oct-31-22 07:30AM	Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates (ACCESSWIRE) +66.38%
Oct-04-22 08:00AM	Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) +8.78%
Sep-26-22 08:00AM	Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee (ACCESSWIRE) +16.15%
Sep-21-22 08:00AM	Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010 (ACCESSWIRE) -12.58%
Sep-16-22 08:30AM	Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split (ACCESSWIRE) -14.10%
Aug-15-22 04:05PM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update (ACCESSWIRE) -9.70%
Jul-22-22 07:00AM	Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
Jul-21-22 07:30AM	Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers (ACCESSWIRE)
Jun-09-22 07:00AM	Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition (ACCESSWIRE) +23.00%
Jun-02-22 09:25AM	Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum (ACCESSWIRE)
May-10-22 08:15AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update (ACCESSWIRE)
Apr-13-22 07:00AM	Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors (ACCESSWIRE) -14.50%
Apr-08-22 01:05PM	Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting (ACCESSWIRE)
Mar-16-22 07:00AM	Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors (ACCESSWIRE) +86.73%
Feb-09-22 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting (ACCESSWIRE)
Feb-08-22 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update (ACCESSWIRE)
Dec-20-21 12:58PM	We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate (Simply Wall St.)
Dec-17-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update (ACCESSWIRE) -7.39%
Aug-30-21 04:01PM	Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) (ACCESSWIRE) +23.43%
Aug-19-21 09:35PM	Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering (ACCESSWIRE) +63.74% -48.25%
Aug-16-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update (ACCESSWIRE) -9.96%
Jun-14-21 07:45AM	Sonnet BioTherapeutics Announces Change in Date of Annual Meeting (ACCESSWIRE)
Jun-08-21 04:30PM	Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology (ACCESSWIRE)
May-17-21 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update (ACCESSWIRE)
May-10-21 06:30AM	Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) (ACCESSWIRE)
May-03-21 06:00AM	Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics (ACCESSWIRE) -12.66%
Mar-29-21 04:30PM	Sonnet BioTherapeutics Provides 2021 Business Update (ACCESSWIRE) -12.08%
Mar-22-21 07:00AM	Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations (ACCESSWIRE)
Feb-16-21 08:10AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update (ACCESSWIRE)
Feb-03-21 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting (ACCESSWIRE)
Feb-01-21 06:30AM	Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates (ACCESSWIRE)
Jan-25-21 06:30AM	Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080 (ACCESSWIRE)
Dec-17-20 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update (ACCESSWIRE) -6.02%
Nov-30-20 08:30AM	Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010 (ACCESSWIRE)
Sep-01-20 08:30AM	Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB) (ACCESSWIRE)
Aug-25-20 07:30AM	Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants (ACCESSWIRE) -18.97%
Aug-24-20 07:37AM	Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod (SmarterAnalyst) +48.29%
Aug-14-20 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update (ACCESSWIRE)
Aug-04-20 07:35AM	Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million (ACCESSWIRE)
07:30AM	Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics (ACCESSWIRE)
Jul-20-20 07:30AM	Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12 (ACCESSWIRE)
Jul-15-20 07:30AM	Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference (ACCESSWIRE) +10.03%
May-18-20 07:30AM	Sonnet BioTherapeutics Holdings Provides Business and Earnings Update (ACCESSWIRE)
Apr-06-20 07:30AM	Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board (ACCESSWIRE)

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SONN

Sonnet BioTherapeutics Holdings Inc

Upgrade your FINVIZ experience